Drugs / RiMO-301
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03444714 | Apr 2018 → Jun 2025 | — | Coordination Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05838729 | Apr 2023 → Sep 2026 overdue | head and neck cancer | Coordination Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RiMO-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03444714 ↗ |
| Route | Other | “via an intratumoral injection” NCT05838729 ↗ |